Biomarkers for cardiovascular disease

challenges and future directions

Abigail Khan, Thomas J. Wang

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

The accurate diagnosis and prevention of cardiovascular disease (CVD) is an important public health goal. Although clinical characteristics such as age and gender are well-established risk factors for CVD, such features are not sufficient to identify all patients at risk. Cardiovascular biomarkers have the potential to augment clinical risk stratification by aiding in screening, diagnosis and assessment of prognosis. However, most current biomarkers have only modest predictive value, and there is a need to identify additional biomarkers from new biological pathways. The availability of platforms for profiling DNA, RNA, proteins and metabolites in clinical specimens has facilitated the 'unbiased' search for new biomarkers, which can now be tested in a clinical setting. This review highlights recent developments in the field of cardiovascular biomarkers and describes the use of new technologies for the identification of biomarkers.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalTrends in Molecular Medicine
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

Cardiovascular Diseases
Biomarkers
DNA Fingerprinting
Direction compound
Public Health
RNA
Technology
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biomarkers for cardiovascular disease : challenges and future directions. / Khan, Abigail; Wang, Thomas J.

In: Trends in Molecular Medicine, Vol. 14, No. 6, 01.06.2008, p. 261-267.

Research output: Contribution to journalReview article

@article{4866089894e04325ad6b2658f161e758,
title = "Biomarkers for cardiovascular disease: challenges and future directions",
abstract = "The accurate diagnosis and prevention of cardiovascular disease (CVD) is an important public health goal. Although clinical characteristics such as age and gender are well-established risk factors for CVD, such features are not sufficient to identify all patients at risk. Cardiovascular biomarkers have the potential to augment clinical risk stratification by aiding in screening, diagnosis and assessment of prognosis. However, most current biomarkers have only modest predictive value, and there is a need to identify additional biomarkers from new biological pathways. The availability of platforms for profiling DNA, RNA, proteins and metabolites in clinical specimens has facilitated the 'unbiased' search for new biomarkers, which can now be tested in a clinical setting. This review highlights recent developments in the field of cardiovascular biomarkers and describes the use of new technologies for the identification of biomarkers.",
author = "Abigail Khan and Wang, {Thomas J.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.molmed.2008.04.003",
language = "English (US)",
volume = "14",
pages = "261--267",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Biomarkers for cardiovascular disease

T2 - challenges and future directions

AU - Khan, Abigail

AU - Wang, Thomas J.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - The accurate diagnosis and prevention of cardiovascular disease (CVD) is an important public health goal. Although clinical characteristics such as age and gender are well-established risk factors for CVD, such features are not sufficient to identify all patients at risk. Cardiovascular biomarkers have the potential to augment clinical risk stratification by aiding in screening, diagnosis and assessment of prognosis. However, most current biomarkers have only modest predictive value, and there is a need to identify additional biomarkers from new biological pathways. The availability of platforms for profiling DNA, RNA, proteins and metabolites in clinical specimens has facilitated the 'unbiased' search for new biomarkers, which can now be tested in a clinical setting. This review highlights recent developments in the field of cardiovascular biomarkers and describes the use of new technologies for the identification of biomarkers.

AB - The accurate diagnosis and prevention of cardiovascular disease (CVD) is an important public health goal. Although clinical characteristics such as age and gender are well-established risk factors for CVD, such features are not sufficient to identify all patients at risk. Cardiovascular biomarkers have the potential to augment clinical risk stratification by aiding in screening, diagnosis and assessment of prognosis. However, most current biomarkers have only modest predictive value, and there is a need to identify additional biomarkers from new biological pathways. The availability of platforms for profiling DNA, RNA, proteins and metabolites in clinical specimens has facilitated the 'unbiased' search for new biomarkers, which can now be tested in a clinical setting. This review highlights recent developments in the field of cardiovascular biomarkers and describes the use of new technologies for the identification of biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=44649108244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649108244&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2008.04.003

DO - 10.1016/j.molmed.2008.04.003

M3 - Review article

VL - 14

SP - 261

EP - 267

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 6

ER -